STOCKHOLM – Japanese scientist Tasuku Honjo was awarded on Monday this year's Nobel Prize in physiology or medicine, for his discovery of a protein that contributed to the development of an immunotherapeutic drug against cancer. Honjo, a 76-year-old professor at Kyoto University, won the prize with U.S. national James Allison, the Nobel Assembly at the Karolinska Institute said. Honjo opened a pathway for a new cancer treatment by discovering the PD-1 protein, which is responsible for suppressing immune response. "I'm very honored and pleased to receive the Nobel Prize in physiology or medicine," Honjo told a news conference following the announcement. His method of treating cancer -- by controlling the protein's function to suppress immunity -- led to the development of Nivolumab, a drug marketed as Opdivo and used against lung cancer and melanoma.
James Allison of the University of Texas and Tasuku Honjo of Kyoto University will share the 9-million-kronor ($1.01 million) prize for 2018. Researchers from the United States and Japan won the Nobel Prize in medicine on Monday for discoveries that help the body marshal its cellular troops to attack invading cancers. One cancer doctor said "an untold number of lives ... have been saved by the science that they pioneered." James Allison of the University of Texas and Tasuku Honjo of Kyoto University will share the 9-million-kronor ($1.01 million) prize for 2018. Their parallel work concerned proteins that act as brakes on the body's immune system.
Three scientists have shared the Nobel physics prize for inventions in the field of laser physics. Arthur Ashkin of the United States won one half of the prize, while Gerard Mourou of France and Donna Strickland of Canada shared the other half'for groundbreaking inventions in the field of laser physics'. Professor Strickland from the University of Waterloo, Canada, is the first women to win the award for 55 years. The announcement comes just hours after Alessandro Strumia of Pisa University was suspended following a'highly offensive' presentation at CERN on gender issues. The Italian physicist said male scientists were the victims of discrimination during a workshop on'High Energy Theory and Gender'.
STOCKHOLM – Japanese scientist Tasuku Honjo, who jointly won this year's Nobel Prize in physiology or medicine for his research on the immune system that contributed to cancer treatments, said Thursday that he believes most cancers will become treatable with immunotherapy by 2050. The 76-year-old professor and deputy director-general at the Kyoto University Institute for Advanced Study spoke at a news conference at the Karolinska Institute in Stockholm, joined by American scientist James Allison, who shared the prize. The discovery by Honjo and Allison -- on methods to inhibit negative immune regulation -- established a new principle for cancer treatment that stimulates the inherent ability of the human immune system to unleash attacks on tumor cells, according to the Nobel Assembly. Honjo said it may become possible to contain the growth of most cancer cells through such treatment, even if cancer cannot be completely eliminated, as he discussed the effectiveness of combination therapy using drugs in the development of which he and Allison were involved. The Kyoto native and his team discovered PD-1, a protein on immune cells that operates as a brake on the immune system.
Two scientists who discovered how to fight cancer using the body's immune system have won the 2018 Nobel Prize for physiology or medicine. The work by James P Allison, from the US, and Tasuku Honjo, from Japan, has led to treatments for advanced, deadly skin cancer. Immune checkpoint therapy has revolutionised cancer treatment, said the prize-giving Swedish Academy. Experts say it has proved to be "strikingly effective". Allison, a professor at the University of Texas, and Honjo, a professor at Kyoto University, will share the Nobel prize sum of nine million Swedish kronor - about $1.01 million or 870,000 euros.